Health Trials

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

ConditionsCancer SurvivorObesityOverweightProstate AdenocarcinomaStage A Prostate CancerStage B Prostate CancerStage C Prostate CancerStage D Prostate CancerStage I Prostate CancerStage II Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage IIC Prostate CancerStage III Prostate CancerStage IIIA Prostate CancerStage IIIB Prostate CancerStage IIIC Prostate CancerStage IV Prostate CancerStage IVA Prostate CancerStage IVB Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorRoswell Park Cancer Institute

About this trial

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.

Eligibility criteria

Qualifiers

Biopsy-confirmed prostate adenocarcinoma of any stage/grade

Prescribed or already receiving continuous ADT for < 5 years

Hemoglobin > 11 g/dL

Creatinine < 1.5 x upper limit of normal (ULN), AST or ALT <2 x ULN within 6 months prior to enrollment

Disqualifiers

Known clinically significant severe chronic obstructive pulmonary disease (COPD), ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias

Limiting orthopedic, musculoskeletal or psychological conditions (clinician discretion)

Overall medical frailty (clinician discretion)

Any condition contraindicating additional blood collection beyond standard of care

Trial design

Treatments tested in this trial

  • Dietary Intervention
  • Educational Intervention
  • Exercise Intervention
  • Quality-of-Life Assessment
  • Survey Administration

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Roswell Park Cancer Institute

Lead sponsor

Source ClinicalTrials.gov